OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

A former biopharma firm that developed cannabinoid-based pain medicines.

OCTHF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVMRB86
LEI:
2138005SRWT4998BCE35
Country:
United Kingdom
Address:
PRAMA HOUSE, 267 BANBURY ROAD, OX2 7HT OXFORD

Description

Oxford Cannabinoid Technologies Holdings PLC was a biopharmaceutical company engaged in the research, development, and commercialization of cannabinoid-based prescription medicines. The company's primary focus was on the pain market, with the goal of developing non-addictive medications to reduce reliance on opioids. Its drug discovery programs targeted the endocannabinoid system (ECS) and included a portfolio of proprietary cannabinoid derivatives, in-licensed compounds, and new chemical entities. According to its website, the company ceased trading and entered administration in May 2025.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-02-19 14:52
Result of General Meeting
English 16.7 KB
2024-02-16 08:00
Completion of Capital Reorganisation
English 11.4 KB
2024-02-15 08:00
Subscription
English 13.3 KB
2024-02-14 13:53
Capital Reorganisation
English 14.7 KB
2024-02-09 08:00
Edison issues update on OCTP
English 5.7 KB
2024-02-02 16:35
Form of Proxy
English 108.8 KB
2024-02-02 16:31
Notice of General Meeting
English 258.9 KB
2024-02-02 16:17
Notice of General Meeting & Posting of Circular
English 15.9 KB
2024-02-02 16:13
Convertible Loan Note Agreements
English 19.0 KB
2024-01-30 10:05
Half Year Report for the period ended 31 October 2023
English 238.7 KB
2024-01-30 08:04
Fundraising and Proposed Capital Reorganisation
English 69.8 KB
2024-01-30 08:02
R&D Tax Credit
English 15.6 KB
2024-01-30 08:00
Half-year Report
English 207.1 KB
2024-01-23 08:00
Notice of Results
English 14.5 KB
2024-01-10 08:00
Patent Applications
English 14.8 KB

Automate Your Workflow. Get a real-time feed of all OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.